Compare Hims and Hers Health Inc (HIMS) vs InMode Ltd (INMD) Price & Performance

Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.

The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.

INMD trades at $14.01, up 0.14% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 earnings of $0.35 per share, beating expectations, and maintains a strong gross profit margin of 76.52%. Recent news includes the launch of Morpheus8 Cool and an unsolicited acquisition offer from Steel Partners at $16.75 per share.

The outlook is mixed: valuation metrics like P/E of 11.63 and EV/EBITDA of 4.48 appear attractive, but declining net income and bearish technicals pose risks. Analyst consensus is divided with 45.45% buy ratings, highlighting potential upside from strategic developments against execution challenges.